Based on the results of the DESTINY-Breast04 study, the FDA has granted accelerated approval for the use of DS-8201 in the treatment of HER2-low expressing breast cancer.129 As of March 2024, the FDA has approved a total of 15 ADC drugs and there are over 500 clinical trials in progress. Here, ERBB2 is linked to breast carcinoma.